University of Extremadura

About: University of Extremadura is a education organization based out in Badajoz, Spain. It is known for research contribution in the topics: Population & Hyperspectral imaging. The organization has 7856 authors who have published 18299 publications receiving 396126 citations. The organization is also known as: Universidad de Extremadura.

Basketball game-related statistics that discriminate between teams’ season-long success

Abstract: The aim of the present study was to identify the game-related statistics that discriminate between season-long successful and unsuccessful basketball teams participating in the Spanish Basketball League (LEB1). The sample included all 145 average records per season from the 870 games played between the 2000–2001 and the 2005–2006 regular seasons. The following game-related statistics were gathered from the official box scores of the Spanish Basketball Federation: 2- and 3-point field-goal attempts (both successful and unsuccessful), free-throws (both successful and unsuccessful), defensive and offensive rebounds, assists, steals, turnovers, blocks (both made and received), and fouls (both committed and received). To control for season variability, all results were normalized to minutes played each season and then converted to z-scores. The results allowed discrimination between best and worst teams’ performances through the following game-related statistics: assists (SC=0.47), steals (SC=0.34), a...

Foreword to the Special Issue on Spectral Unmixing of Remotely Sensed Data

Abstract: The 19 papers in this special issue focus on the state-of-the-art and most recent developments in the area of spectral unmixing of remotely sensed data.

Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.

Abstract: Objective Our objective was to identify genetic factors related to interindividual variability in the pharmacokinetics of ibuprofen and its enantiomers. Methods The time course for ibuprofen plasma concentration was measured by HPLC in 130 healthy individuals who received a single oral dose of 400 mg racemic ibuprofen. Genomic deoxyribonucleic acid was analyzed for common mutations at CYP2C8 and CYP2C9 genes that cause amino acid substitutions. Results Ibuprofen clearance values were 4.04 L/h (95% confidence interval [CI], 3.61–4.47 L/h), 2.79 L/h (95% CI, 2.07–3.52 L/h), and 0.40 L/h (95% CI, 0.37–0.43 L/h) for carriers of CYP2C8 genotypes *1/*1, *1/*3, and *3/*3, respectively, and 4.43 L/h (95% CI, 3.94–4.92 L/h), 3.26 L/h (95% CI, 2.53–3.99 L/h), 2.91 L/h (95% CI, 1.52–4.30 L/h), 2.05 L/h (95% CI, 0–6.37 L/h), 1.83 L/h (95% CI, 1.24–2.41 L/h), and 1.13 L/h (95% CI, 0.58–1.66 L/h) for carriers of the CYP2C9 genotypes *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3, respectively. The P values for comparison across nonmutated, heterozygous, and homozygous genotypes were as follows: P < .001 for CYP2C8*3, P < .005 for CYP2C9*2, and P < .001 for CYP2C9*3. The main genetic factor for reduced clearance of R-(−)-ibuprofen is the CYP2C8*3 allele, whereas the clearance for S-(+)-ibuprofen is influenced by CYP2C8*3 and CYP2C9*3 alleles to a similar extent. The CYP2C9*2 allele was associated with low clearance only when it was present in combination with the CYP2C8*3 allele. As compared with individuals with no mutations, individuals with the common genotype CYP2C8*1/*3 plus CYP2C9*1/*2 (19% of the population) displayed decreased ibuprofen clearance (mean, 65% [95% CI, 42%–89%]; P < .001). Individuals homozygous or double-heterozygous for CYP2C8*3 and CYP2C9*3 variant alleles (8% of the population) had extremely low ibuprofen clearance rates, with values ranging from 7% to 27% of the mean clearance rates among noncarriers of mutations (P < .001). No enantiospecific reduction of ibuprofen clearance was observed. Conclusion Low ibuprofen clearance occurs in a substantial proportion of healthy subjects, is not enantiospecific, and is strongly linked to CYP2C8 and CYP2C9 polymorphisms. Clinical Pharmacology & Therapeutics (2004) 76, 119–127; doi: 10.1016/j.clpt.2004.04.006